CN104360062A - Application of peptidylarginine deiminase 1 (PAD1) to preparation of reagent for clinical diagnosis of tumors - Google Patents
Application of peptidylarginine deiminase 1 (PAD1) to preparation of reagent for clinical diagnosis of tumors Download PDFInfo
- Publication number
- CN104360062A CN104360062A CN201410714949.8A CN201410714949A CN104360062A CN 104360062 A CN104360062 A CN 104360062A CN 201410714949 A CN201410714949 A CN 201410714949A CN 104360062 A CN104360062 A CN 104360062A
- Authority
- CN
- China
- Prior art keywords
- reagent
- pad1
- blood
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of peptidylarginine deiminase 1 (PAD1) to preparation of a clinically diagnostic reagent or detection object for diagnosing tumors. The tumors are selected from uterine cancers, liver cancers, gastric cancers, esophageal cancers, ovarian cancers and lung cancers. When PAD1 is specially applied, an antibody against PAD1 is prepared by a conventional method, and a qualitative or quantitative method and a matching kit for detecting PAD1 are established. The invention also discloses a blood diagnosis reagent for diagnosing tumors. The blood diagnosis reagent comprises the PAD1 antibody, a horseradish peroxidase-immunoglobulin G (HRP-IgG) antibody and conventional reagents in the blood diagnosis reagent, wherein the conventional reagents in the blood diagnosis reagent include a carbonate buffer solution, a phosphate buffer solution-Tween (PBST) lotion, a blocking solution, developing solutions and a stop solution. PAD1 is found for the first time to be capable of being applied as a tumor blood marker. Experiments prove that PAD1 has feasibility as the tumor marker.
Description
Technical field
The present invention relates to Peptidylarginine deiminase 1 and prepare the application in clinical tumor Blood diagnosis reagent as tumor blood mark.
Background technology
Peptidylarginine deiminase (Peptidylarginine deiminase, PAD or PADI) is a kind of enzyme in tissue, at present, has found five kinds of PAD enzymes (i.e. PAD/PADIl, 2,3,4 and 6) altogether.These enzymes by the cluster coded by said gene be seated on human chromosomal lp36 region, and have different Tissue distribution.It can calcium ion deposit in case some other histone is carried out after translation modify (post-translational modification).The amino of the arginine (arginine) in polypeptied chain can be catalyzed into carbonyl by this enzyme, thus makes conversion of Arginine become citrulline (citrulline).Citrulline is a non-natural amino acid.This becomes the process of citrulline to be referred to as citrullinated (citrullination) by conversion of Arginine in the polypeptide of PAD catalysis.Because structure changes after albumen generation is citrullinated, its enzymatic activity, metabolic activity, regulatory function and structure function is caused all to change.Therefore, citrullinated be with phosphorylation, acetylation, glycosylation, methylate, modification mode after the same important protein translation of ubiquitination.
In recent years, by the research of immunology, cellular biochemistry and molecular genetics, PAD4 (PADI4, Peptidylarginine deiminase 4, or PADI4) be proved to be play very important effect in mankind's rheumatoid arthritis pathogenic process, and can be used as adenocarcinoma marker, apply in preparation gland cancer reagent for clinical diagnosis.PAD1 (Peptidylarginine deiminase 1, Peptidylarginine deiminase 1, or PADI1) although and PAD4 be all Peptidylarginine deiminase, there is different Tissue distribution, do not have at present about the relevant report of PAD1 as tumor blood mark.
Summary of the invention
For above-mentioned prior art, the present invention obtains a kind of new tumor blood mark by research---and Peptidylarginine deiminase 1 (PAD1/PADI1), can be used for the clinical diagnosis of tumour.
The present invention is achieved by the following technical solutions:
The present invention studies Late Cambrian by experiment, compare with normal human serum with benign tumour patients serum, chronic inflammation patients serum, the expression of PAD1 in the sera of patients with malignant tumors such as liver cancer, knot/carcinoma of the rectum, breast cancer, Esophageal and cardiac cancer obviously increases.PAD1 can express simultaneously in Several Kinds of Malignancy patients serum, this is that fewer (current tumor blood label Sensitivity and Specificity is undesirable in the tumor marker used at present, clinical existing tumour serum label reaches more than 20 and plants, but the overwhelming majority often can only be used for detecting a kind of tumour, Sensitivity and Specificity is poor, and joint-detection usually can only be adopted could to provide significant data for clinical diagnosis).PAD1 expression in blood and known cancer label level compare by the present invention, and find that PAD1 lesion detection positive rate and specificity are not second to CEA, broad spectrum activity is higher than CA125, CA199, PSA, CA242 etc.
Based on above discovery, PAD1 has higher specificity as the application of tumour serum label, for this reason, the present invention have developed the tumor diagnosis kit and detection method that diagnostic area is wide, susceptibility is strong, specificity is high, clinical tumor preliminary investigation and health screening can be widely used in, for clinical diagnosis provides reliable basis.
Particularly, prepare anti-Peptidylarginine deiminase 1 antibody in conventional manner, set up the qualitative or quantivative approach and matched reagent box that detect Peptidylarginine deiminase 1.
A Blood diagnosis reagent for diagnosing tumour, comprises Peptidylarginine deiminase 1 antibody, HRP-IgG antibody, and the conventional reagent in Blood diagnosis reagent.
Conventional reagent in described Blood diagnosis reagent comprises carbonate buffer solution, PBST washing lotion, confining liquid, nitrite ion and stop buffer.
Further, detection method is indirect ELISA method qualitatively, and its principle is utilize the antiantibody of enzyme labeling (human immunoglobulins's antibody) to examine antibody to detect being subject to of being combined with solid phase antigen, and concrete mode is as follows:
(1), after blood sample carbonate buffer solution (pH9.6) to be detected being diluted 10 times, add in blank ELISA Plate, 37 DEG C of incubation 2h;
(2) discard liquid in hole, PBST washing lotion washes plate three times (described PBST washing lotion refers to that PBS solution adds Tween-20, and the pH of PBS solution is the concentration of 7.4, Tween-20 is 0.1%, percent by volume);
(3) every hole adds confining liquid (0.5%BSA, mass percent) 200 μ L/ hole, 37 DEG C of incubation 1h;
(4) discard liquid in hole, PBST washing lotion washes plate three times;
(5) often group adds PAD1 antibody diluent (1:2000 dilution) 100 μ L/ hole, 37 DEG C of incubation 1h;
(6) discard liquid in hole, PBST washing lotion washes plate three times;
(7) every hole adds HRP-IgG antibody diluent (1:3000 dilution) 100 μ L, 37 DEG C of incubation 1h;
(8) discard liquid in hole, PBST washing lotion washes plate five times;
(9) every hole adds nitrite ion A, B[developer A (containing hydrogen peroxide) for hydrogen donor (DH2), and substrate B is exactly developer B (containing TMB, 3,3', 5,5'-tetramethyl benzidine)] each 50 μ L, 37 DEG C of colour developing 10min.
(10) every hole adds 50 μ L stop buffer (2M H
2sO
4solution) color development stopping, shake even, detect OD by microplate reader
450nmvalue;
(11) calculate: with negative serum (normal human serum) for contrast, detect negative serum OD
450nmaverage (being for the out average again value of control test with many parts of negative serums); By OD
450nmvalue substitutes into formula P/N value=blood sample OD to be measured
450nmvalue/negative serum OD
450nmaverage, calculates the P/N value of blood sample to be detected;
(12) judge: if the P/N value of blood sample to be detected is more than or equal to 2.1, then the testing result of this blood sample to be detected be the positive, and this patient belonging to blood sample to be detected likely suffers from tumour, one of foundation that can be used as clinical diagnosis.
Above-mentioned involved antibody, for being prepared by a conventional method to obtain.Above-mentioned involved various reagent, are existing conventional reagent in prior art.
In like manner, when quantitatively detecting, also adopt above-mentioned Cleaning Principle, the standard items of preparation series concentration, then drawing standard product concentration and OD
450nmvalue or OD
630nmthe typical curve of value, and obtain equation of linear regression, then by the OD of blood sample to be detected
450nmvalue or OD
630nmvalue substitutes into typical curve, tries to achieve the concentration in sample.
Further, when quantitatively detecting, adopt double-antibody sandwich elisa to detect PAD1, step is as follows:
(1) bag quilt: PAD1 monoclonal antibody 1 coating buffer (carbonate buffer solution of pH9.6) is diluted to 1 μ g/mL, adds in blank ELISA Plate, 100 μ L/ holes, 4 DEG C of saturated humidity left overnight;
(2) wash plate: discard liquid in hole, every hole adds PBST washing lotion 300 μ L, and (described PBST washing lotion refers to that PBS solution adds Tween-20, and the pH of PBS solution is 7.4, the concentration 0.1% of Tween-20, percent by volume), soak 15 seconds, get rid of and abandon liquid.Wash plate continuously three times;
(3) close: every hole adds confining liquid (0.5%BSA, mass percent) 200 μ L/ hole, 37 DEG C of incubation 1h;
(4) plate is washed three times, same to step (2);
(5) set: stay a hole to make blank, any liquid wouldn't be added; Separately establish PAD1 standard items 7 hole, respectively add 100 μ L standard items;
(6) application of sample: after blood sample PBST to be detected is diluted 10 times, add in order in reacting hole, incubated at room 1.5h;
(7) plate is washed three times, same to step (2);
(8) enzyme-added: each hole adds PAD1 monoclonal antibody dilution (1/3000) (not the comprising blank) that 100 μ LHRP mark, incubated at room 45min;
(9) plate is washed three times, same to step (2);
(10) develop the color: every hole adds nitrite ion A, B[developer A (containing hydrogen peroxide) successively for hydrogen donor (DH2), substrate B is exactly that developer B is (containing TMB, 3,3', 5,5'-tetramethyl benzidine)] each 50 μ L (comprising blank), concussion mixing, room temperature lucifuge develops the color 10 minutes;
(11) stop: every hole adds each 50 μ L (comprising blank) of stop buffer, concussion mixing cessation reaction;
(12) measure: with blank control wells zeroing, and measured each hole OD value with microplate reader Single wavelength 450nm in 30 minutes; Also each hole OD value can be measured with dual wavelength 450nm/630nm;
(13) calculate: with the logarithm value of serial standards concentration value for horizontal ordinate (X-axis), with the logarithm value of standard items OD value for ordinate (Y-axis), set up (log-log) typical curve, calculate the PAD1 content of sample to be tested.
In addition, detection method also can be colloidal gold method qualitatively, its Cleaning Principle is: adopt double antibody sandwich method and colloid gold immune technology, colloidal gold pad adds anti-PAD1 antibody colloidal gold bond in advance, the detection line and control line of nitrocellulose filter are coated with anti-PAD1 antibody respectively.When detecting, as being positive sample, PAD1 in sample can mark anti-PAD1 antibody with gold and be combined and form compound, and because chromatography effect compound moves forward along test paper, then the antibody pre-coated with detection line is combined and forms " golden labeling antibody-PAD1-antibody " compound and aggegation develops the color.Nitrocellulose membrane is coated with a nature controlling line in contrast simultaneously, therefore is judged to the positive when appearance red nature controlling line and a red response line.When in sample to be checked without PAD1 antigen time, only occur that a red nature controlling line is judged to feminine gender.As Quality Control, no matter result is positive or negative, all can occur a red nature controlling line.If occur without red line (or only having response line), then it is invalid to detect.Concrete detection method is:
(1) with the clean a small amount of sample of container collection, (serum sample is venous collection according to a conventional method; The sample gathered detected in five days, need place 4 DEG C of preservations, within more than five days, needed to place-20 DEG C of preservations, avoided multigelation; If muddy or precipitation appears in sample, answer centrifugal or detect again after filtering clarification); Open inner packing, take out Test paper.
(2) operate according to product type:
1. detector bar: detector bar is indicated (noting: liquid level did not have MAX line) taking-up in 30 seconds in one end immersion sample of MAX printed words and lie against on table top.
2. test card: indicate in the well of " S " printed words in test card, drips 4 samples (about 100 μ l) with dropper.
(3) there is rear timing in bar nature controlling line to be detected (C line), observations in 20 minutes, and after 20 minutes, observations is invalid.
The explanation of assay:
(1) negative findings: only occur nature controlling line (C line).
(2) positive findings: occur two lines, i.e. nature controlling line (C line) and detection line (T line).
(3) null result: wireless appearance, or only there is detection line (T line), must again detect.
Late Cambrian PAD1 of the present invention can high expressed in the cell of the Several Kinds of Malignancies such as the cancer of the uterus, liver cancer, cancer of the stomach, the cancer of the esophagus, lung cancer and oophoroma and in blood, therefore, PAD1 can apply as tumor blood mark, the experiment proved that, its specificity is not second to CEA, and broad spectrum activity is higher than CA242, CA125, PSA, CA199 etc.Although PAD1 expresses in kinds of tumors, do not reach absolute specificity, but, one of ordinary skill in the art are known, the specific non-of clinical detection index can not negate uniquely definitely the feasibility of Testing index as one of the means diagnosing relevant disease, and such as several Testing index is often made final diagnosis in conjunction with clinical manifestation by doctor.Therefore, PAD1 has feasibility as tumor markers; Although PAD1 has not exclusive specificity, PAD1 is also enough to be used in detecting tumour (this mode is also current normal method clinically) as tumor blood mark in conjunction with other Testing index and clinical manifestation.In addition, the present invention also finds, PAD1 also can be used as the detection that blood markers thing is applied to the other diseases such as inflammation, as hepatitis B, general inflammation (have leucocyte, neutrophilic leukocytosis, the symptom that lymphocyte ratios reduces), ephrosis (comprising nephrotic syndrome, kidney failure, ephritis), uremia (comprising uremia and urinary tract infections), the clinical diagnosis that also can be used as the Other diseases such as inflammation according to one of.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.
Reagent, method etc. involved in following embodiment, unless otherwise noted, be conventional reagent of the prior art, method.
Embodiment 1 PAD1 is as the detection example 1 of tumor blood mark
Using PAD1 as tumor blood mark, the blood of tumor patient is detected, the number of cases of tumor patient and suffer from tumour kind refer to table 1.
Detection method is:
(1), after blood sample carbonate buffer solution (pH9.6) to be detected being diluted 10 times, add in blank ELISA Plate, 37 DEG C of incubation 2h;
(2) discard liquid in hole, PBST washing lotion washes plate three times (described PBST washing lotion refers to that PBS solution adds Tween-20, and the pH of PBS solution is the concentration of 7.4, Tween-20 is 0.1%, percent by volume);
(3) every hole adds confining liquid (0.5%BSA, mass percent) 200 μ L/ hole, 37 DEG C of incubation 1h;
(4) discard liquid in hole, PBST washing lotion washes plate three times;
(5) often group adds PAD1 antibody diluent (1:2000 dilution) 100 μ L/ hole, 37 DEG C of incubation 1h;
(6) discard liquid in hole, PBST washing lotion washes plate three times;
(7) every hole adds HRP-IgG antibody diluent (1:3000 dilution) 100 μ L, 37 DEG C of incubation 1h;
(8) discard liquid in hole, PBST washing lotion washes plate five times;
(9) every hole adds nitrite ion A, B[developer A (containing hydrogen peroxide) for hydrogen donor (DH2), and substrate B is exactly developer B (containing TMB, 3,3', 5,5'-tetramethyl benzidine)] each 50 μ L, 37 DEG C of colour developing 10min.
(10) every hole adds 50 μ L stop buffer (2M H
2sO
4solution) color development stopping, shake even, detect OD by microplate reader
450nmvalue;
(11) calculate: with negative serum (normal human serum) for contrast, detect negative serum OD
450nmaverage (being for the out average again value of control test with many parts of negative serums); By OD
450nmvalue substitutes into formula P/N value=blood sample OD to be measured
450nmvalue/negative serum OD
450nmaverage, calculates the P/N value of blood sample to be detected;
(12) judge: if the P/N value of blood sample to be detected is more than or equal to 2.1, then the testing result of this blood sample to be detected is positive.
Result: positive number of cases and positive rate are in table 1, the positive rate of other tumor markers is in table 2 (for the disclosed data of energy in prior art), and can be found out by table 1, table 2, PAD1 is as tumor blood mark, there is good specificity, broad spectrum activity.
Table 1
| Tumour classification | Total number of cases | Positive number of cases | Positive rate |
| The cancer of the uterus | 654 | 510 | 78.0％ |
| Liver cancer | 537 | 399 | 74.3％ |
| Cancer of the stomach | 363 | 219 | 60.3％ |
| The cancer of the esophagus | 252 | 147 | 58.3％ |
| Lung cancer | 387 | 251 | 64.8％ |
| Oophoroma | 387 | 195 | 50.4％ |
| Amount to | 2580 | 1721 | 66.7％ |
Table 2
| Tumour classification | PAD1 | CEA | CA199 | CA125 | CA242 |
| The cancer of the uterus | 78.0％ | - | - | - | - |
| Liver cancer | 74.3％ | 62％～75％ | 65％ | - | - |
| Lung cancer | 64.8％ | 56％～80％ | 44％ | 50％ | |
| Cancer of the stomach | 60.3％ | 60％～90％ | 50％ | 47％ | - |
| The cancer of the esophagus | 58.3％ | - | - | - | 62％ |
| Oophoroma | 50.4％ | - | 35％ | 61.4％ | - |
Embodiment 2 PAD1 is as the detection example 2 of tumor blood mark
Using PAD1 as tumor blood mark, detect the blood of patient, detection method is with embodiment 1.Meanwhile, using CEA, CA199, F/PSA, CA125, PSA, CA242, AFP, HCG, NSE of the prior art as tumor blood mark, the blood of tumor patient is detected to (detection method is conventional method of the prior art; The blood examination data of these tumor blood marks of the prior art are patient's Outpatient Department data of certain hospital, and these data can as one of diagnosis patient foundation whether suffering from tumour; The present invention brings again the blood examination PAD1 of some patients).Contrast the positive rate of each tumor blood mark, and PAD1 compared with intersecting of each tumor markers.
Result: the number of cases (totally 906 examples) of patient and the number of cases of the detection positive are in table 3.Can be found out by table 3, PAD1 can apply as tumor blood mark, and its specificity is good.
Table 3 PAD1 compared with intersecting of each tumor markers
Embodiment 3 PAD1 is as the detection example 3 of blood markers thing
Using PAD1 as blood markers thing, to hepatitis B, general inflammation (leucocyte, neutrophilic leukocytosis, the patient that lymphocyte ratios reduces), ephrosis (comprising nephrotic syndrome, kidney failure, ephritis), uremia (comprising uremia and urinary tract infections) patient blood detect, the number of cases of patient and the kind suffered from the disease refer to table 4.
Detection method is with embodiment 1.
Result: positive number of cases and positive rate are in table 4, can be found out by table 4, PAD1 is as blood markers thing, also may be used for detecting hepatitis B, general inflammation and (there is leucocyte, neutrophilic leukocytosis, the symptom that lymphocyte ratios reduces), the disease such as ephrosis (comprising nephrotic syndrome, kidney failure, ephritis), uremia (comprising uremia and urinary tract infections), testing result can as clinical diagnosis according to one of.
Table 4
| Disease category | Total number of cases | Positive number of cases | Positive rate |
| Hepatitis B | 394 | 34 | 8.6％ |
| General inflammation | 225 | 8 | 3.6％ |
| Ephrosis | 133 | 8 | 6.0％ |
| Uremia | 110 | 20 | 18.2％ |
Claims (9)
1. Peptidylarginine deiminase 1 is in the reagent for clinical diagnosis preparing diagnosing tumour or the application detected in thing.
2. application according to claim 1, is characterized in that: described tumour is selected from the cancer of the uterus, liver cancer, cancer of the stomach, the cancer of the esophagus, oophoroma, lung cancer.
3. the application of Peptidylarginine deiminase 1 in the reagent for clinical diagnosis or detection thing of preparation diagnosis inflammation, described inflammation is selected from hepatitis B, general inflammation, ephrosis, uremia.
4. the application according to claim 1 or 2 or 3, is characterized in that: prepare anti-Peptidylarginine deiminase 1 antibody in conventional manner, sets up the qualitative or quantivative approach and matched reagent box that detect Peptidylarginine deiminase 1.
5. a Blood diagnosis reagent for diagnosing tumour, is characterized in that: comprise Peptidylarginine deiminase 1 antibody, HRP-IgG antibody, and the conventional reagent in Blood diagnosis reagent.
6. the Blood diagnosis reagent of diagnosing tumour according to claim 5, is characterized in that: described tumour is selected from the cancer of the uterus, liver cancer, cancer of the stomach, the cancer of the esophagus, oophoroma, lung cancer.
7. the Blood diagnosis reagent of the diagnosing tumour according to claim 5 or 6, is characterized in that: the conventional reagent in described Blood diagnosis reagent comprises carbonate buffer solution, PBST washing lotion, confining liquid, nitrite ion and stop buffer.
8. diagnose a Blood diagnosis reagent for inflammation, it is characterized in that: comprise Peptidylarginine deiminase 1 antibody, HRP-IgG antibody, and the conventional reagent in Blood diagnosis reagent; Described inflammation is selected from hepatitis B, general inflammation, ephrosis, uremia.
9. the Blood diagnosis reagent of diagnosis inflammation according to claim 8, is characterized in that: the conventional reagent in described Blood diagnosis reagent comprises carbonate buffer solution, PBST washing lotion, confining liquid, nitrite ion and stop buffer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410714949.8A CN104360062B (en) | 2014-11-28 | 2014-11-28 | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared |
| PCT/CN2015/077352 WO2016082444A1 (en) | 2014-11-28 | 2015-04-24 | Application of peptidylarginine deiminase 1 in preparation of reagent for clinical diagnosis of tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410714949.8A CN104360062B (en) | 2014-11-28 | 2014-11-28 | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104360062A true CN104360062A (en) | 2015-02-18 |
| CN104360062B CN104360062B (en) | 2017-03-08 |
Family
ID=52527343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410714949.8A Active CN104360062B (en) | 2014-11-28 | 2014-11-28 | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104360062B (en) |
| WO (1) | WO2016082444A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016082444A1 (en) * | 2014-11-28 | 2016-06-02 | 山东创新药物研发有限公司 | Application of peptidylarginine deiminase 1 in preparation of reagent for clinical diagnosis of tumors |
| CN108254558A (en) * | 2018-02-11 | 2018-07-06 | 山东省千佛山医院 | Applications of the PADI3 in colon cancer is diagnosed and/or treated |
| CN110927390A (en) * | 2019-12-16 | 2020-03-27 | 广东省农业科学院动物卫生研究所 | ELISA method and kit for detecting African swine fever CD2v protein antibody and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733932A (en) * | 2005-07-18 | 2006-02-15 | 山东省医药生物技术研究中心 | Adenocarcinoma marker and its uses |
| JP2006053113A (en) * | 2004-08-16 | 2006-02-23 | Medical Proteoscope Co Ltd | Method and kit for diagnosing pulmonary adenocarcinoma lymph node metastasis |
| CN101101290A (en) * | 2006-11-30 | 2008-01-09 | 山东省医药生物技术研究中心 | Tumour serum mark and its uses |
| CN101121944A (en) * | 2006-11-30 | 2008-02-13 | 山东省医药生物技术研究中心 | Rheumatoid arthritis knuckle synovia marker and application thereof |
| CN101273144A (en) * | 2005-07-27 | 2008-09-24 | 肿瘤疗法科学股份有限公司 | Method of diagnosing esophageal cancer |
| JP2009156615A (en) * | 2007-12-25 | 2009-07-16 | Tokyo Metropolitan Foundation For Social Welfare & Public Health | Method for measuring pad 4 and anti-pad 4 antibody and method of detecting articular rheumatism |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002342053A1 (en) * | 2001-10-11 | 2003-04-22 | The Johns Hopkins University | Pancreatic cancer diagnosis and therapies |
| WO2010060103A1 (en) * | 2008-11-24 | 2010-05-27 | Loma Linda University | Biomarkers for the detection of head and neck tumors |
| CN104360062B (en) * | 2014-11-28 | 2017-03-08 | 山东新创生物科技有限公司 | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared |
-
2014
- 2014-11-28 CN CN201410714949.8A patent/CN104360062B/en active Active
-
2015
- 2015-04-24 WO PCT/CN2015/077352 patent/WO2016082444A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006053113A (en) * | 2004-08-16 | 2006-02-23 | Medical Proteoscope Co Ltd | Method and kit for diagnosing pulmonary adenocarcinoma lymph node metastasis |
| CN1733932A (en) * | 2005-07-18 | 2006-02-15 | 山东省医药生物技术研究中心 | Adenocarcinoma marker and its uses |
| CN101273144A (en) * | 2005-07-27 | 2008-09-24 | 肿瘤疗法科学股份有限公司 | Method of diagnosing esophageal cancer |
| CN101101290A (en) * | 2006-11-30 | 2008-01-09 | 山东省医药生物技术研究中心 | Tumour serum mark and its uses |
| CN101121944A (en) * | 2006-11-30 | 2008-02-13 | 山东省医药生物技术研究中心 | Rheumatoid arthritis knuckle synovia marker and application thereof |
| JP2009156615A (en) * | 2007-12-25 | 2009-07-16 | Tokyo Metropolitan Foundation For Social Welfare & Public Health | Method for measuring pad 4 and anti-pad 4 antibody and method of detecting articular rheumatism |
Non-Patent Citations (5)
| Title |
|---|
| CELINE FOULQUIER ET AL: "Peptidyl Arginine Deiminase Type 2 (PAD-2) and PAD-4 but Not PAD-1, PAD-3, and PAD-6 Are Expressed in Rheumatoid Arthritis Synovium in Close Association With Tissue Inflammation", 《ARTHRITIS & RHEUMATISM》 * |
| CHU CHEN ET AL: "Gene expression profiling identifies genes predictive of oral squamous cell carcinoma", 《CANCER EPIDEMIOL BIOMARKERS PREV》 * |
| SUNISH MOHANAN ET AL: "Potential Role of Peptidylarginine Deiminase Enzymes and Protein Citrullination in Cancer Pathogenesis", 《BIOCHEMISTRY RESEARCH INTERNATIONAL》 * |
| 孟庆松等: "PADI4在类风湿关节炎患者血液中的表达", 《兰州大学学报》 * |
| 左传同: "肽基精氨酸脱亚胺酶4在结肠癌中的表达及意义", 《医学信息》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016082444A1 (en) * | 2014-11-28 | 2016-06-02 | 山东创新药物研发有限公司 | Application of peptidylarginine deiminase 1 in preparation of reagent for clinical diagnosis of tumors |
| CN108254558A (en) * | 2018-02-11 | 2018-07-06 | 山东省千佛山医院 | Applications of the PADI3 in colon cancer is diagnosed and/or treated |
| CN110927390A (en) * | 2019-12-16 | 2020-03-27 | 广东省农业科学院动物卫生研究所 | ELISA method and kit for detecting African swine fever CD2v protein antibody and application |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016082444A1 (en) | 2016-06-02 |
| CN104360062B (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106053812B (en) | A kind of a variety of autoantibody joint-detection ELISA kits for being used for liver cancer early screening and diagnosis | |
| CN105572354B (en) | A kind of antibody chip kit for detecting early carcinoma of stomach | |
| CN106248940B (en) | The system of multi objective Combining diagnosis oophoroma and/or the malignant tumour of non-ovary origin | |
| CN103364558A (en) | Human tumor marker carcinoembryonic antigen (CEA) magnetic particle chemiluminiscence immunoassay kit and detection method | |
| CN201477101U (en) | Transferrin and hemoglobin combined detection board | |
| CN102901820A (en) | Immunoassay kit and immunodetection method for magnetic particle chemiluminescence of human tumor marker carbohydrate antigen 50 (CA50) | |
| CN110187109A (en) | A kind of autoantibody joint-detection ELISA kit for Grades of Gastric Cardia Adenocarcinoma early screening | |
| CN104360070B (en) | Application of peptidylarginine deiminase 2 (PAD2) to preparation of reagent for clinical blood diagnosis of tumors | |
| CN105548547A (en) | Flow type array immunoassay kit for detecting lung cancer markers based on flow cytometry | |
| CN104360062B (en) | Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared | |
| Chen et al. | Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test | |
| CN101377513A (en) | Chromogranin A chemiluminescence immune analysis quantitative determination reagent kit and preparing method thereof | |
| CN104374907B (en) | A kind of indirect competitive enzyme-linked aptamers detects the method for Determination of oxytetracycline residues | |
| CN102680706B (en) | Application of protein CTSF (Cathepsin F) in preparation of reagent for diagnosing gastric cancer and diagnostic reagent kit | |
| US20180164320A1 (en) | Method for diagnosis of colorectal cancer using mass spectrometry of n-glycans | |
| CN107462725B (en) | Application and its kit of the IgG antibody of anti-FNDC4 as gastric cancer serum marker | |
| CN1325917C (en) | Method for prediagnosing cancer and reagent box | |
| CN105259348B (en) | A kind of secreting type Sema4C albumen and its application | |
| CN109001453B (en) | A kind of kit based on lysozyme content in latex immunoturbidimetry detection human body fluid sample | |
| CN109239332A (en) | A kind of kit of auxiliary detection sub-health population cancer base antigen | |
| CN107144688B (en) | CD19 positive excretion bodies are as application of the molecular labeling in preparing tumor diagnosis kit and kit | |
| CN106680512B (en) | A kind of quick detection kit of NMP-22 and its application | |
| CN112129954B (en) | Application of MMP7, CTSE or LAMC2 protein in preparation of intrahepatic cholangiocellular carcinoma diagnostic reagent | |
| CN104849459B (en) | ELISA kit and the application thereof of PSA | |
| CN110261611B (en) | Application of ZNF709 protein as gastric cancer serum biomarker and kit thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170207 Address after: 250101 Shandong city of Ji'nan province high tech Zone Port three northbound Ji'nan Valley No. 1 building B room 2206 Applicant after: Shandong Xinchuang biological science and Technology Co Ltd Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Applicant before: Shandong Chuangxin Pharmaceutial Research and Development Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |